TB Drug Accelerator Program

Aiming to speed up the discovery and development of novel compounds against tuberculosis (TB).
Pharma (non-IFPMA member) 2
Private Foundation or Development Organization 1
Academia or research institute 8
Global NGOs 1
Government 1
  • The TB Drug Accelerator Programme aims to speed up the discovery and development of novel compounds against tuberculosis (TB).

Health need and challenges the partnership is targeting

Despite significant progress in combatting tuberculosis (TB), TB B is one of the top 10 causes of death and the leading cause from a single infectious agent. According to WHO, in 2017, TB caused an estimated 1.3 million deaths among HIV-negative people and there were an additional 300,000 deaths from TB among HIV-positive people. Globally, the best estimate is that 10.0 million people developed TB disease in 2017. It is estimated that one-quarter of the global population has latent tuberculosis infection, of whom approximately 10% will develop active pulmonary tuberculosis disease. In recent years, the emergence of multi-drug resistant TB and extensively drug-resistant TB has increased pressure to urgently control the disease and epidemic, particularly in countries with a high rate of HIV. As a result of years of inadequate diagnosis and treatment, these types of drug-resistant TB are more difficult and costlier to treat, highlighting the urgent need for new, better, faster-acting treatments.

Partnership activities and how they address needs and challenges

Launched in August 2012, TB Drug Accelerator (TBDA) is a ground-breaking partnership between pharmaceutical companies and research organizations with support from the Bill & Melinda Gates Foundation.

Aided by nearly U.S. $20 million (approx. €16.5 million) from the Gates Foundation, the TBDA aims to develop new pre-clinical drug candidates with treatment-shortening potential and provide proof-of-concept for a one-month three-drug regime, by 2022.

The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month, rather than the 6 months now needed for treatment.

Eli Lilly and Company is a former member of this initiative.

We seek a common goal to give patients and physicians significantly more effective treatments for TB and drug-resistant TB. Without new regimens, we cannot stop this global pandemic.
Mel Spigelman, M.D.
President and Chief Executive Officer, TB Alliance
Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Men
  • Women
Partner organizations
Pharma (non-IFPMA member)



Private Foundation or Development Organization

Bill and Melinda Gates Foundation

Academia or research institute

The California Institute for Biomedical Research (Calibr)

Infectious Disease Research Institute (IDRI)

Texas A&M University

University of Cape Town

University of Colorado

University of Dundee

University of Medicine and Dentistry of New Jersey

Weill Medical College, Cornell University

Global NGOs

Global Alliance for TB Drug Development (TB Alliance)


US National Institutes of Health (NIH)

Additional resources